Innovating Works

CERMEL

ACROBAT Newborns: Appraising the Critical Role of prognostic Biomarkers in the Assessment and Triage of sick African n... The main concern of clinicians when addressing sick patients is to promptly identify -i.e., not miss- those at higher risk of severe disease...
2024-10-28 - 2029-12-31 | Financiado
ASAAP-plus: Clinical evaluation of AntimalarialS tri-therapy with AtovAquone-Proguanil for treatment of uncompli... Centre de Recherches Medicales de Lambaréné participó en un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2023-01 Susceptibility to Artemisinin-based combination therapies (ACTs) currently remains high among the African Plasmodium falciparum population,...
2024-03-11 - 2025-12-31 | Financiado
VICI-DISEASE: PROTECTION FROM VIRUSES WITH EPIDEMIC AND PANDEMIC DISEASE OUTBREAK POTENTIAL THROUGH DEVELOPMENT AN... Centre de Recherches Medicales de Lambaréné participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-03 The enormous health and economic impacts of epidemics and pandemics has become one of the defining public policy and health issues in Europe...
2023-11-13 - 2027-11-30 | Financiado
eWHORM: Enabling the WHO-Roadmap 2030 Centre de Recherches Medicales de Lambaréné participó en un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 We will establish for the first time in NTDs an adaptive clinical trial platform and improve clinical research infrastructure in four SSA co...
2023-03-02 - 2028-03-31 | Financiado
EChiLiBRiST: Development and validation of a quantitative point of care test for the measurement of severity biom... Centre de Recherches Medicales de Lambaréné participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 "Fever is the leading reason to seek healthcare globally, with over 1 billion cases of febrile illness occurring in children annually. The v...
2022-07-18 - 2027-08-31 | Financiado
ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS CoV 2 Pandemic ORCHES... Centre de Recherches Medicales de Lambaréné participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 The ORCHESTRA project provides an innovative approach to learn from the SARS-CoV-2 health crisis and derive recommendations for increasing p...
2020-11-06 - 2024-11-30 | Financiado
VSV-EBOPLUS: SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE Sofia ref. 11606... Centre de Recherches Medicales de Lambaréné participó en un H2020: H2020-JTI-IMI2-2015-08-single-stage The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycopr...
2017-06-12 - 2023-03-31 | Financiado
VSV-EBOVAC: Vaccine safety and immunogenicity signatures of human responses to VSV ZEBOV Sofia ref. 115842 Centre de Recherches Medicales de Lambaréné participó en un H2020: H2020-JTI-IMI2-2014-02-single-stage The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promis...
2015-03-19 - 2019-02-28 | Financiado
IDEA: Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections An... Centre de Recherches Medicales de Lambaréné participó en un FP7: Worm infections are receiving increased attention due to: the wide geographic overlap in occurrence between worms and HIV, TB and malaria; t...
Financiado
HOOKVAC: Developing and Testing a novel low cost effective HOOKworm VACcine to Control Human Hookworm Infec... Centre de Recherches Medicales de Lambaréné participó en un FP7: Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm...
Financiado
THESCHISTOVAC: The targeted development of a new generation Vaccine for Schistosomiasis Centre de Recherches Medicales de Lambaréné participó en un FP7: The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or gly...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.